Healthcare provider profile · identity verified

Andrew Gallagher

Allopathic & Osteopathic Physicians|General Practice · MANCHESTER, CT · NPI 1518429588

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Andrew Gallagher received $66.93 in general payments during 2025 across 2 reported records.

Boston Scientific Corporation accounted for 52.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$66.93

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Boston Scientific Corporation Unresolved — no canonical attribution shown $35.4252.9%12025
Exact Sciences Corporation Unresolved — no canonical attribution shown $31.5147.1%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$66.932

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
ACCOLADE SR
Normalized: accolade sr
Device Boston Scientific Corporation $35.42 1 2025
Source payment records
The Cologuard Plus Collection Kit
Normalized: the cologuard plus collection kit
Device Exact Sciences Corporation $31.51 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium588178
Levothyroxine SodiumLevothyroxine Sodium29076
Losartan PotassiumLosartan Potassium24077
Amlodipine BesylateAmlodipine Besylate23875
OmeprazoleOmeprazole20161
LisinoprilLisinopril19262
Metoprolol SuccinateMetoprolol Succinate16648
Rosuvastatin CalciumRosuvastatin Calcium12637
HydrochlorothiazideHydrochlorothiazide12434
Metformin HclMetformin Hcl12439
Pantoprazole SodiumPantoprazole Sodium11626
Fluticasone PropionateFluticasone Propionate10228
Metformin Hcl ErMetformin Hcl10231
EliquisApixaban9918
SimvastatinSimvastatin9931
Tamsulosin HclTamsulosin Hcl9330
Trazodone HclTrazodone Hcl8321
FamotidineFamotidine7821
Pravastatin SodiumPravastatin Sodium7722
Albuterol Sulfate HfaAlbuterol Sulfate7321
JardianceEmpagliflozin7213
LorazepamLorazepam7218
ChlorthalidoneChlorthalidone6420
FinasterideFinasteride6219
FurosemideFurosemide6020
Montelukast SodiumMontelukast Sodium6013
AllopurinolAllopurinol5820
Sertraline HclSertraline Hcl5415
Diclofenac SodiumDiclofenac Sodium48suppressed
EzetimibeEzetimibe4714
GabapentinGabapentin4518
IndapamideIndapamide43suppressed
Hydroxyzine HclHydroxyzine Hcl42suppressed
Escitalopram OxalateEscitalopram Oxalate3811
Fluoxetine HclFluoxetine Hcl35suppressed
OzempicSemaglutide35suppressed
SpironolactoneSpironolactone3511
Citalopram HbrCitalopram Hydrobromide3412
MirtazapineMirtazapine32suppressed
Zolpidem TartrateZolpidem Tartrate32suppressed
Propranolol Hcl ErPropranolol Hcl30suppressed
ColchicineColchicine2811
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28suppressed
Promethazine HclPromethazine Hcl28suppressed
TradjentaLinagliptin28suppressed
LidocaineLidocaine27suppressed
Tramadol HclTramadol Hcl26suppressed
Potassium ChloridePotassium Chloride2511
Sumatriptan SuccinateSumatriptan Succinate25suppressed
TrulicityDulaglutide25suppressed
GlimepirideGlimepiride24suppressed
AtenololAtenolol23suppressed
Glipizide ErGlipizide23suppressed
Paroxetine HclParoxetine Hcl21suppressed
SynthroidLevothyroxine Sodium21suppressed
Verapamil ErVerapamil Hcl21suppressed
Alendronate SodiumAlendronate Sodium20suppressed
FarxigaDapagliflozin Propanediol20suppressed
GlipizideGlipizide20suppressed
Omega-3 Acid Ethyl EstersOmega-3 Acid Ethyl Esters18suppressed
Triamcinolone AcetonideTriamcinolone Acetonide18suppressed
Clonidine HclClonidine Hcl17suppressed
Duloxetine HclDuloxetine Hcl17suppressed
Doxazosin MesylateDoxazosin Mesylate16suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16suppressed
Olmesartan MedoxomilOlmesartan Medoxomil15suppressed
AmoxicillinAmoxicillin14suppressed
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic14suppressed
Amitriptyline HclAmitriptyline Hcl13suppressed
CefadroxilCefadroxil13suppressed
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13suppressed
Oxycodone HclOxycodone Hcl13suppressed
Repatha SureclickEvolocumab13suppressed
Terazosin HclTerazosin Hcl13suppressed
Ultra-Fine Short Pen NeedlePen Needle, Diabetic13suppressed
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12suppressed
Dilt-XrDiltiazem Hcl12suppressed
Oxybutynin Chloride ErOxybutynin Chloride12suppressed
CarvedilolCarvedilol11suppressed
MeloxicamMeloxicam11suppressed
NystatinNystatin11suppressed
Ondansetron HclOndansetron Hcl11suppressed
TorsemideTorsemide11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $66.93 · 2 records Boston Scientific Corporation ACCOLADE SR, The Cologuard Plus Collection Kit
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error